Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)‐TIMI 53 trial
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Background and aims: SAVOR‐TIMI 53 was designed to study the effects of the DPP‐4 inhibitor saxagliptin on cardiovascular outcomes in high risk type 2 diabetes patients with diverse levels of diabetes control and background anti‐diabetic drugs. The goal of this article is to describe the baseline characteristics of this hypothesis driven study. Materials and methods: A total of 16 496 diabetic patients from North America (31.9%), Western Europe (26.0%), Eastern Europe (17.3%), Latin America (16.4%) and Asia (8.3%), with either established cardiovascular disease (78.3%) or with ≥two additional cardiovascular risk factors (21.7%) were randomised to saxagliptin or placebo. Biomarkers of inflammation and insulin resistance were taken at baseline and 2 years later in order to correlate saxagliptin effect on cardiovascular outcome to its effect on inflammation and insulin resistance. Results: Mean [+/−standard deviation (SD)] age was 65.0 (+/−8.6) years, 66.9% were male, body mass index was 31.2 kg/m 2 (+/−5.6), mean diabetes duration was 11.9 years (+/−8.9) and the mean HbA 1c 8.0% (+/−1.4%). HbA 1c < 7% was most prevalent among North Americans (30.8%) and least among Asians (15.1%), whereas HbA 1c > 9% was 30.7% in Latin America 27.0% in Asia and 15.1% in North America. Diabetic retinopathy was reported in 12.3% of patients, nephropathy in 17.7% and amputation in 2.5%. Diabetic treatments categories were as follows: no medication (5.4%), 1 oral anti‐diabetic drug (OAD) (25.0%), ≥2 OAD (27.7%) and/or insulin (40.9%). The prevalence of micro‐albuminuria was twice as high among insulin users compared with users of ≥2 OAD. Baseline statin use (78.3% overall) varied by region. Conclusion: The SAVOR‐TIMI 53 patient population, with differing background diabetes control and anti‐diabetic treatment, provides global representation of diabetic patients with established cardiovascular disease or at high risk for cardiovascular disease and is well‐positioned to determine the effect of saxagliptin on cardiovascular events. Copyright © 2013 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675 · cited 1×
“Over the last decade, the concern has been raised, and not truly resolved, regarding potential CV risk with certain anti-diabetic drugs (ADD), especially rosiglitazone [12,13] and certain drug combinations [14–16].”
BackgroundMortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes
and the WHO Multinational Study Group, Morrish, N. J., Wang, S.-L., Stevens, L. K., Fuller, J. H., & Keen, H. (2001) · Diabetologia · doi:10.1007/pl00002934 · Cited by 1,288 · cited 1×
“Type 2 diabetes patients are at increased risk for first and repeated cardiovascular (CV) events [1,2].”
BackgroundBan, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057 · cited 12×
“Drugs whose mode of action is through the incretin system [dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors) and glucagon-like peptide-1 receptor agonists (GLP-1 R agonists)] were the first to be licenced according to new regulatory guidelines [17,18] that were published by the USA Food and Drug Administration and…”
BackgroundInfluentialLong-term effects of intensive glucose lowering on cardiovascular outcomes
The ACCORD Study Group (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1006524 · Cited by 1,035 · cited 2×
“However, tight glycemic control in protocols studying high risk patients at later stages of the disease for shorter periods did not demonstrate a reduction in CV events or mortality [5,6,8,9].”
BackgroundResultNikolaidis, L. A., Mankad, S., Sokos, G. G., Miske, G., Shah, A., Elahi, D., & Shannon, R. P. (2004) · Circulation · doi:10.1161/01.cir.0000120505.91348.58 · Cited by 901 · cited 2×
“Short-term GLP-1 infusion in patients with acute MI, left ventricular dysfunction and successful revascularization was shown to improve LVEF [26].”
BackgroundSokos, G. G., Nikolaidis, L. A., Mankad, S., Elahi, D., & Shannon, R. P. (2006) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2006.08.211 · Cited by 656
Bennett, W. L., Maruthur, N. M., Singh, S., Segal, J. B., Wilson, L. M., Chatterjee, R., Marinopoulos, S. S., Puhan, M. A., Ranasinghe, P., Block, L., et al. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-9-201105030-00336 · Cited by 609
Noyan-Ashraf, M. H., Momen, M. A., Ban, K., Sadi, A.-M., Zhou, Y.-Q., Riazi, A. M., Baggio, L. L., Henkelman, R. M., Husain, M., & Drucker, D. J. (2009) · Diabetes · doi:10.2337/db08-1193 · Cited by 575
Evans, J. M. M., Ogston, S. A., Emslie-Smith, A., & Morris, A. D. (2006) · Diabetologia · doi:10.1007/s00125-006-0176-9 · Cited by 293
Nikolaidis, L. A., Elahi, D., Shen, Y.-T., & Shannon, R. P. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00347.2005 · Cited by 274 · cited 1×
“GLP-1 (9–36), an active metabolite derived from native GLP-1 (7–36) amide after cleavage by DPP-4, has been shown to exert cardio-protective actions in rodents [32] and improve CV function in dogs with congestive heart failure [33].”
BackgroundBasu, A., Charkoudian, N., Schrage, W., Rizza, R. A., Basu, R., & Joyner, M. J. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00373.2007 · Cited by 226
Ta, N. N., Schuyler, C. A., Li, Y., Lopes-Virella, M. F., & Huang, Y. (2011) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e31821e5626 · Cited by 156 · cited 1×
“DPP-4 inhibitors have been shown to inhibit atherosclerosis in Zucker diabetic fatty rats [37], diabetic apoE-deficient mice [44] and in male low-density lipoprotein receptors-depleted mice [45].”
BackgroundWhite, W. B., Bakris, G. L., Bergenstal, R. M., Cannon, C. P., Cushman, W. C., Fleck, P., Heller, S., Mehta, C., Nissen, S. E., Perez, A., et al. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.08.004 · Cited by 152
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Price, D. L., Chen, R., Udell, J., et al. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.08.006 · Cited by 106
Self-citation
Cited by
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Self-citationClinical Use of DPP-4 Inhibitors
Gallwitz, B. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00389 · Cited by 374
Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial
Mosenzon, O., Leibowitz, G., Bhatt, D. L., Cahn, A., Hirshberg, B., Wei, C., Im, K., Rozenberg, A., Yanuv, I., Stahre, C., et al. (2017) · Diabetes Care · doi:10.2337/dc16-0621 · Cited by 268
Self-citationEfficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial
Leiter, L. A., Teoh, H., Braunwald, E., Mosenzon, O., Cahn, A., Kumar, K. M. P., Smahelova, A., Hirshberg, B., Stahre, C., Frederich, R., et al. (2015) · Diabetes Care · doi:10.2337/dc14-2868 · Cited by 87
Self-citationPetrie (2016) · doi:10.1097/hjh.0000000000000890 · Cited by 20
Metadata
- Authors
- Mosenzon, O., Raz, I., Scirica, B. M., Hirshberg, B., Stahre, C. I., Steg, P. G., Davidson, J., Ohman, P., Price, D. L., Frederich, B., Udell, J. A., Braunwald, E., & Bhatt, D. L.
- Venue
- Diabetes/Metabolism Research and Reviews
- Publisher
- Wiley
- Published
- 2013-05-21
- Volume
- 29
- Issue
- 5
- Pages
- 417-426
- ISSN
- 1520-7552 (ISSN-L)
- 1520-7560
- OpenAlex
- W1494561942
- Cited by
- 52
- References
- 15
- FWCI
- 6.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.